High-resolution Genetic Mapping of Maternal Effects and Epistatic Suppressors of Congenital Heart Disease Risk
High-resolution Genetic Mapping of Maternal Effects and Epistatic Suppressors of Congenital Heart Disease Risk
批准号:
9256806
负责人:
Ehiole Ogboma Akhirome
金额:
$3.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-02-01 至 2020-07-31
关键词:
AdultAgeAgingAneuploidyAnimal ModelBioinformaticsBiological ModelsCandidate Disease GeneCardiacChildChromosome MappingClinicalDatabasesEnvironmentExerciseFamilyGene-ModifiedGeneral PopulationGenerationsGenesGeneticGenetic PolymorphismGenetic VariationHeart AbnormalitiesHumanInbred StrainIncidenceIndividualInterventionLaboratoriesLinear ModelsLongevityMapsMaternal AgeMethodsModelingMolecularMorbidity - disease rateMothersMusMutateMutationNewborn InfantOperative Surgical ProceduresPathogenesisPlaguePopulationPreventionProcessQuantitative GeneticsResearch Project GrantsResolutionRiskRoleTestingTherapeuticTranslatingWorkage effectcongenital anomalycongenital heart disorderdisorder preventiondisorder riskeggexperienceexperimental studygenetic manipulationgenetic variantmortalitymouse modelnoveloffspringpediatric patientsreproductivesuccesstherapeutic targettraittranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT
Congenital heart disease (CHD) is the most common congenital anomaly, which leads to significant
morbidity and mortality in newborns. Although great surgical advances have reduced CHD mortality in newborns
and children, these patients are not cured. Many of these children grow up and experience serious morbidity and
truncated lifespans as adults. It has become evident that we need strategies to move our efforts away from
intervention and toward prevention. The first step in this endeavor is to understand the causes of CHD.
Surprisingly, environment and mutations are estimated to explain less than one-third of CHD cases. In many
cases, however, even when a vital cardiac gene is mutated, a heart defect does not occur. This highlights the
critical role that genetic modifiers have in CHD pathogenesis. Attempts to identify these modifier genes have had
marginal success in humans. This motivated us to look toward animal models, in which we can control the effects
of environment and genetics.
Our mouse model replicates CHD risk in susceptible people through a heterozygous mutation in Nkx2-5,
an essential cardiac transcription factor. We then use inbred strain crosses and quantitative genetic methods to
identify genetic polymorphisms that modify CHD risk in Nkx2-5+/- mice. Through this model system, we
inadvertently confirmed observations in humans that the offspring of older mothers have an elevated risk for CHD
even after ruling out aneuploidy. We also determined that this risk is due to factors within old mothers, not old
eggs. Remarkably, voluntary exercise for the aging mother is sufficient to reduce CHD risk to baseline levels.
Subsequent studies demonstrated that the magnitude of the maternal aging risk varied according to the genetic
background of our mice. This indicates that the age risk is a quantitative trait that regulates maternal factors,
which can either inflate or suppress the risk of CHD. In separate experiments focused on risk modifiers within
susceptible individuals, I discovered genetic loci that act as epistatic suppressors of CHD risk in multiple mouse
populations. If we were able to identify the genes responsible and mimic the effects of maternal exercise or
protective genetic loci, we could translate these benefits to the general population. Our past experiments were not
designed to detect individual genes. So instead of speculating about the genes responsible for the maternal age-
associated risk and epistatic suppression of CHD, we have chosen a prudent and unbiased approach to identify
these genes. We have partnered with the laboratory of James Cheverud to use a high-resolution, advanced
intercross mapping population to identify CHD modifier loci to nearly single-gene resolution. This study will be
the first to map novel genes and variants that modify CHD risk at high-resolution, and these results will serve as
a springboard for future research into congenital heart disease prevention.
We propose these specific aims:
AIM 1: Identify high-resolution genetic loci that modify the maternal age-associated risk of CHD.
AIM 2: Map high-resolution genetic loci and detect epistatic suppressors of CHD risk in the offspring.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
High-resolution Genetic Mapping of Maternal Effects and Epistatic Suppressors of Congenital Heart Disease Risk
-
批准号:9424419
-
项目类别:
-
资助金额:$3.12万
-
财政年份:2017
-
负责人:Ehiole Ogboma Akhirome
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: